Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J W Clark

Showing results (201-210 of 213) with videos related to

Pageof 22
Sort By:
Journal of the National Cancer Institute|June 17, 1992
Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinomaM Sznol, J W Clark, J W Smith, et al.
Journal of the National Cancer Institute|April 19, 1989
Intraperitoneal lymphokine-activated killer cell/interleukin-2 therapy in patients with intra-abdominal cancer: immunologic considerationsW J Urba, J W Clark, R G Steis, et al.
Cancer Research|April 1, 1989
Randomized trial of recombinant alpha 2b-interferon with or without indomethacin in patients with metastatic malignant melanomaR L Miller, R G Steis, J W Clark, et al.
Journal of the National Cancer Institute|February 7, 1990
Low- versus high-dose interferon alfa-2a in relapsed indolent non-Hodgkin's lymphomaL A VanderMolen, R G Steis, P L Duffey, et al.
Cancer|January 5, 2000
A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumorsD P Ryan, T J Lynch, M L Grossbard, et al.
Journal of the National Cancer Institute|April 18, 1990
Recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy: a phase Ib trialR G Steis, L A VanderMolen, D L Longo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1990
Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavityR G Steis, W J Urba, L A VanderMolen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 31, 2014
Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLCS-H I Ou, P A Jänne, C H Bartlett, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 14, 2009
Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancerP C Enzinger, D P Ryan, J W Clark, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2013
Phase I/II study of neoadjuvant bevacizumab, erlotinib and 5-fluorouracil with concurrent external beam radiation therapy in locally advanced rectal cancerL S Blaszkowsky, D P Ryan, J Szymonifka, et al.
Pageof 22

Showing results (201-210 of 213) with videos related to

Sort By:
Pageof 22
Journal of the National Cancer Institute|June 17, 1992
Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinomaM Sznol, J W Clark, J W Smith, et al.
Journal of the National Cancer Institute|April 19, 1989
Intraperitoneal lymphokine-activated killer cell/interleukin-2 therapy in patients with intra-abdominal cancer: immunologic considerationsW J Urba, J W Clark, R G Steis, et al.
Cancer Research|April 1, 1989
Randomized trial of recombinant alpha 2b-interferon with or without indomethacin in patients with metastatic malignant melanomaR L Miller, R G Steis, J W Clark, et al.
Journal of the National Cancer Institute|February 7, 1990
Low- versus high-dose interferon alfa-2a in relapsed indolent non-Hodgkin's lymphomaL A VanderMolen, R G Steis, P L Duffey, et al.
Cancer|January 5, 2000
A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumorsD P Ryan, T J Lynch, M L Grossbard, et al.
Journal of the National Cancer Institute|April 18, 1990
Recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy: a phase Ib trialR G Steis, L A VanderMolen, D L Longo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1990
Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavityR G Steis, W J Urba, L A VanderMolen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 31, 2014
Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLCS-H I Ou, P A Jänne, C H Bartlett, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 14, 2009
Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancerP C Enzinger, D P Ryan, J W Clark, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2013
Phase I/II study of neoadjuvant bevacizumab, erlotinib and 5-fluorouracil with concurrent external beam radiation therapy in locally advanced rectal cancerL S Blaszkowsky, D P Ryan, J Szymonifka, et al.
Pageof 22